Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Renee Ott

Nurse Practitioner, Family Sandusky, OH Nurse Practitioner

NPI 1124168026 CMS profile 11150062

2500 W Strub Rd Ste 330, Dermatology Partners INC, Sandusky, OH 44870

Open in the dashboard

General payments

$178,713

2,358 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Renee Ott of Sandusky, OH is reported in the CMS Open Payments database as having received $178,713 across 2,358 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,847 544
2024 General $57,222 556
2023 General $42,870 513
2022 General $20,620 420
2021 General $6,155 325

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Renee Ott
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Renee Ott were reported at $51,847. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Renee Ott Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $6,155 $124 $35–$379 $132
2022 $20,620 $141 $44–$430 $149
2023 $42,870 $154 $49–$476 $160
2024 $57,222 $165 $51–$504 $164
2025 $51,847 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Incyte Corporation $34,119 163 payments
  2. Organon LLC $29,045 77 payments
  3. Regeneron Healthcare Solutions, Inc. $25,319 185 payments
  4. Genzyme Corporation $17,034 62 payments
  5. Dermavant Sciences, Inc. $10,752 129 payments
  6. Galderma Laboratories, L.P. $8,643 135 payments
  7. Sun Pharmaceutical Industries Inc. $7,861 236 payments
  8. AbbVie, Inc. $7,178 347 payments
  9. EPI Health, LLC $5,506 22 payments
  10. Verrica Pharmaceuticals Inc. $4,041 16 payments
  11. Other $29,214 986 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,869 58 payments
  2. Food and Beverage $53,147 2,155 payments
  3. Travel and Lodging $24,681 99 payments
  4. Consulting Fee $23,213 21 payments
  5. Honoraria $11,550 8 payments
  6. Education $1,253 17 payments
Products named General payments · program years 2021–2025
  1. VTAMA $39,633 191 payments
  2. OPZELURA $31,179 150 payments
  3. DUPIXENT Immunology $22,535 77 payments
  4. DUPIXENT Inflammation And Immunology $21,531 140 payments
  5. NEMLUVIO $6,752 28 payments
  6. WYNZORA $5,506 22 payments
  7. YCANTH $4,041 16 payments
  8. Otezla $4,030 88 payments
  9. DUPIXENT Immunology And Inflammation $3,671 40 payments
  10. LEVULAN KERASTICK $3,491 11 payments
  11. Other $43,687 1,930 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,270

Median for Nurse Practitioner: 389

Drug cost

$548,545

Median for Nurse Practitioner: $21,885

Branded share of claims

12.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 32 $215,028
Enbrel Sureclick Etanercept Brand 18 $127,730
Dupixent Pen Dupilumab Brand 30 $114,061
Otezla Apremilast Brand 13 $62,753
Clobetasol Propionate Generic 132 $4,750
Fluocinonide Generic 84 $4,100
Clindamycin Phosphate Generic 85 $3,196
Fluocinolone Acetonide Generic 48 $2,982
Triamcinolone Acetonide Generic 207 $2,671
Ketoconazole Generic 229 $2,562

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$85,491

Of which drugs: $7,395

Medicare patients

704

Average age 73

Services billed

2,938

443 women, 261 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 48%
Diabetes 21%
Ischemic heart disease 17%
Chronic kidney disease 17%
Cancer 16%
Depression 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 19 25 $7,378
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 30 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
$17,882 — —
DUPIXENT
$14,314 30 —
OPZELURA
$10,150 — —
YCANTH
$3,852 — —
Otezla
$2,538 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

2,358 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record